1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
2
|
Sim X, Ali RA, Wedren S, Goh DL, Tan CS,
Reilly M, Hall P and Chia KS: Ethnic differences in the time trend
of female breast cancer incidence: Singapore, 1968–2002. BMC
Cancer. 6:2612006. View Article : Google Scholar : PubMed/NCBI
|
3
|
Gujam FJ, Going JJ, Edwards J, Mohammed ZM
and McMillan DC: The role of lymphatic and blood vessel invasion in
predicting survival and methods of detection in patients with
primary operable breast cancer. Crit Rev Oncol Hematol. 89:231–241.
2014. View Article : Google Scholar : PubMed/NCBI
|
4
|
Hack CC, Voiß P, Lange S, Paul AE, Conrad
S, Dobos GJ, Beckmann MW and Kümmel S: Local and systemic therapies
for breast cancer patients: Reducing Short-term symptoms with the
methods of integrative medicine. Geburtshilfe Frauenheilkd.
75:675–682. 2015. View Article : Google Scholar : PubMed/NCBI
|
5
|
Nagaraj G, Ellis MJ and Ma CX: The natural
history of hormone receptor-positive breast cancer: Attempting to
decipher an intriguing concept. Oncology (Williston Park).
26:696–700. 2012.PubMed/NCBI
|
6
|
Tang Y, Wang Y, Kiani MF and Wang B:
Classification, treatment strategy and associated drug resistance
in breast cancer. Clin Breast Cancer. 16:335–343. 2016. View Article : Google Scholar : PubMed/NCBI
|
7
|
Rybárová S, Hodorová I, Hajduková M,
Schmidtová K, Mojzis J, Kajo K, Kviatkovská Z, Plank L, Benický M,
Mirossay A, et al: Expression of MDR proteins in breast cancer and
its correlation with some clinical and pathological parameters.
Neoplasma. 53:128–135. 2006.PubMed/NCBI
|
8
|
Zaragozá R, García-Trevijano ER, Lluch A,
Ribas G and Viña JR: Involvement of different networks in mammary
gland involution after the pregnancy/lactation cycle: Implications
in breast cancer. IUBMB Life. 67:227–238. 2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Espinoza-Fonseca LM: Targeting MDM2 by the
small molecule RITA: Towards the development of new multi-target
drugs against cancer. Theor Biol Med Model. 2:382005. View Article : Google Scholar : PubMed/NCBI
|
10
|
Núñez C, Capelo JL, Igrejas G, Alfonso A,
Botana LM and Lodeiro C: An overview of the effective combination
therapies for the treatment of breast cancer. Biomaterials.
97:34–50. 2016. View Article : Google Scholar : PubMed/NCBI
|
11
|
Ma P and Mumper RJ: Paclitaxel
nano-delivery systems: A comprehensive review. J Nanomed
Nanotechnol. 4:10001642013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Wang Y, Fu Q and Zhao W:
Tetramethylpyrazine inhibits osteosarcoma cell proliferation via
downregulation of NF-κB in vitro and in vivo. Mol Med Rep.
8:984–988. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Li WM, Liu HT, Li XY, Wu JY, Xu G, Teng
YZ, Ding ST and Yu C: The effect of tetramethylpyrazine on hydrogen
peroxide-induced oxidative damage in human umbilical vein
endothelial cells. Basic Clin Pharmacol Toxicol. 106:45–52.
2010.PubMed/NCBI
|
14
|
Zheng CY, Xiao W, Zhu MX, Pan XJ, Yang ZH
and Zhou SY: Inhibition of cyclooxygenase-2 by tetramethylpyrazine
and its effects on A549 cell invasion and metastasis. Int J Oncol.
40:2029–2037. 2012.PubMed/NCBI
|
15
|
Yin J, Yu C, Yang Z, He JL, Chen WJ, Liu
HZ, Li WM, Liu HT and Wang YX: Tetramethylpyrazine inhibits
migration of SKOV3 human ovarian carcinoma cells and decreases the
expression of interleukin-8 via the ERK1/2, p38 and AP-1 signaling
pathways. Oncol Rep. 26:671–679. 2011.PubMed/NCBI
|
16
|
Wang XB, Wang SS, Zhang QF, Liu M, Li HL,
Liu Y, Wang JN, Zheng F, Guo LY and Xiang JZ: Inhibition of
tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug
resistant human hepatocellular carcinoma cells. Oncol Rep.
23:211–215. 2010.PubMed/NCBI
|
17
|
Zhang Y, Liu X, Zuo T, Liu Y and Zhang JH:
Tetramethylpyrazine reverses multidrug resistance in breast cancer
cells through regulating the expression and function of
P-glycoprotein. Med Oncol. 29:534–538. 2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Zhang P, Zheng BB, Wang HY, Chen JH, Liu
XY and Guo XL: DLJ14, a novel chemo-sensitization agent, enhances
therapeutic effects of adriamycin against MCF-7/A cells both in
vitro and in vivo. J Pharm Pharmacol. 66:398–407. 2014. View Article : Google Scholar : PubMed/NCBI
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Tang ZY, Wang SL and Lin Y: Progress in
the pharmacokinetics and clinical pharmacodynamics of
tetramethylpyrazine in nervous system. Chin J Clin Pharmacol.
26:535–539. 2010.
|
21
|
Fu YS, Lin YY, Chou SC, Tsai TH, Kao LS,
Hsu SY, Cheng FC, Shih YH, Cheng H, Fu YY and Wang JY:
Tetramethylpyrazine inhibits activities of glioma cells and
glutamate neuro-excitotoxicity: Potential therapeutic application
for treatment of gliomas. Neuro Oncol. 10:139–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
22
|
Chen L, Lu Y, Wu JM, Xu B, Zhang LJ, Gao
M, Zheng SZ, Wang AY, Zhang CB, Zhang WW and Lei N: Ligustrazine
inhibits B16F10 melanoma metastasis and suppresses angiogenesis
induced by vascular endothelial growth factor. Biochem Biophys Res
Commun. 386:374–379. 2009. View Article : Google Scholar : PubMed/NCBI
|
23
|
Wang S, Lei T and Zhang M: The reversal
effect and its mechanisms of tetramethylpyrazine on multidrug
resistance in human bladder cancer. PLoS One. 11:e01577592016.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Yang XG and Jiang C: Ligustrazine as a
salvage agent for patients with relapsed or refractory
non-Hodgkin's lymphoma. Chin Med J (Engl). 123:3206–3211.
2010.PubMed/NCBI
|
25
|
Cao J, Miao Q, Miao S, Bi L, Zhang S, Yang
Q, Zhou X, Zhang M, Xie Y, Zhang J and Wang S: Tetramethylpyrazine
(TMP) exerts antitumor effects by inducing apoptosis and autophagy
in hepatocellular carcinoma. Int Immunopharmacol. 26:212–220. 2015.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Wang XJ, Xu YH, Yang GC, Chen HX and Zhang
P: Tetramethylpyrazine inhibits the proliferation of acute
lymphocytic leukemia cell lines via decrease in GSK-3β. Oncol Rep.
33:2368–2374. 2015. View Article : Google Scholar : PubMed/NCBI
|
27
|
Chen J, Wang W, Wang H, Liu X and Guo X:
Combination treatment of ligustrazine piperazine derivate DLJ14 and
adriamycin inhibits progression of resistant breast cancer through
inhibition of the EGFR/PI3K/Akt survival pathway and induction of
apoptosis. Drug Discov Ther. 8:33–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
28
|
Pan J, Shang JF, Jiang GQ and Yang ZX:
Ligustrazine induces apoptosis of breast cancer cells in vitro and
in vivo. J Cancer Res Ther. 11:454–458. 2015. View Article : Google Scholar : PubMed/NCBI
|
29
|
Mundi PS, Sachdev J, McCourt C and
Kalinsky K: AKT in cancer: New molecular insights and advances in
drug development. Br J Clin Pharmacol. 82:943–956. 2016. View Article : Google Scholar : PubMed/NCBI
|
30
|
Matson DR, Hardin H, Buehler D and Lloyd
RV: AKT activity is elevated in aggressive thyroid neoplasms where
it promotes proliferation and invasion. Exp Mol Pathol.
103:288–293. 2017. View Article : Google Scholar : PubMed/NCBI
|
31
|
Robert M, Frenel JS, Bourbouloux E, Berton
Rigaud D, Patsouris A, Augereau P, Gourmelon C and Campone M:
Efficacy of buparlisib in treating breast cancer. Expert Opin
Pharmacother. 18:2007–2016. 2017. View Article : Google Scholar : PubMed/NCBI
|
32
|
Zhu L, Tian G, Yang Q, De G, Zhang Z, Wang
Y, Nie H, Zhang Y, Yang X and Li J: Thyroid hormone receptor β1
suppresses proliferation and migration by inhibiting PI3K/Akt
signaling in human colorectal cancer cells. Oncol Rep.
36:1419–1426. 2016. View Article : Google Scholar : PubMed/NCBI
|
33
|
Lim W, Jeong M, Bazer FW and Song G:
Coumestrol inhibits proliferation and migration of prostate cancer
cells by regulating AKT, ERK1/2 and JNK MAPK cell signaling
cascades. J Cell Physiol. 232:862–871. 2016. View Article : Google Scholar : PubMed/NCBI
|
34
|
Clark PA, Bhattacharya S, Elmayan A,
Darjatmoko SR, Thuro BA, Yan MB, van Ginkel PR, Polans AS and Kuo
JS: Resveratrol targeting of AKT and p53 in glioblastoma and
glioblastoma stem-like cells to suppress growth and infiltration. J
Neurosurg. 126:1448–1460. 2016. View Article : Google Scholar : PubMed/NCBI
|
35
|
Han XG, Du L, Qiao H, Tu B, Wang YG, Qin
A, Dai KR, Fan QM and Tang TT: CXCR1 knockdown improves the
sensitivity of osteosarcoma to cisplatin. Cancer Lett. 369:405–415.
2015. View Article : Google Scholar : PubMed/NCBI
|
36
|
Yamaguchi M, Osuka S, Weitzmann MN, Shoji
M and Murata T: Increased regucalcin gene expression extends
survival in breast cancer patients: Overexpression of regucalcin
suppresses the proliferation and metastatic bone activity in
MDA-MB-231 human breast cancer cells in vitro. Int J Oncol.
49:812–822. 2016. View Article : Google Scholar : PubMed/NCBI
|
37
|
Jiang Q, Pan Y, Cheng Y and Li H, Liu D
and Li H: Lunasin suppresses the migration and invasion of breast
cancer cells by inhibiting matrix metalloproteinase-2/-9 via the
FAK/Akt/ERK and NF-κB signaling pathways. Oncol Rep. 36:253–262.
2016. View Article : Google Scholar : PubMed/NCBI
|
38
|
Yang SX, Polley E and Lipkowitz S: New
insights on PI3K/AKT pathway alterations and clinical outcomes in
breast cancer. Cancer Treat Rev. 45:87–96. 2016. View Article : Google Scholar : PubMed/NCBI
|
39
|
Ried SJ and Shi Y: Molecular mechanisms of
caspase regulation during apoptosis. Nat Rev Mol Cell Biol.
5:897–907. 2004. View
Article : Google Scholar : PubMed/NCBI
|
40
|
Fan LL, Sun GP, Wei W, Wang ZG, Ge L, Fu
WZ and Wang H: Melatonin and doxorubicin synergistically induce
cell apoptosis in human hepatoma cell lines. World J Gastroenterol.
16:1473–1481. 2010. View Article : Google Scholar : PubMed/NCBI
|
41
|
Wang L, Jin F, Qin A, Hao Y, Dong Y, Ge S
and Dai K: Targeting Notch1 signaling pathway positively affects
the sensitivity of osteosarcoma to cisplatin by regulating the
expression and/or activity of Caspase family. Mol Cancer.
13:1392014. View Article : Google Scholar : PubMed/NCBI
|